GlassScriptPhysician profile
Mohammad Kamgar
NPI 1275788440
$496,813.07
in general payments reported to CMS, 2019-2025
18 companies · $82K in 2025
The $82K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $16K · 2021: $66K · 2022: $114K · 2023: $105K · 2024: $77K · 2025: $82K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $114K · Consulting Fee: $65K · Travel and Lodging: $33K · Honoraria: $32K · Food and Beverage: $11K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $6,800 · Education: $21.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $114,282.00 |
| Consulting Fee | $65,125.00 |
| Travel and Lodging | $32,937.19 |
| Honoraria | $32,450.00 |
| Food and Beverage | $11,413.53 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $6,800.00 |
| Education | $21.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $142,847.33 | 2019-2025 | Jynarque, Voyxact |
| Aurinia Pharma U.S., INC. | $121,020.12 | 2021-2025 | Lupkynis |
| Glaxosmithkline, LLC. | $68,034.23 | 2020-2025 | Benlysta, Jesduvroq |
| Travere Therapeutics, INC. | $66,788.15 | 2023-2025 | Filspari |
| Calliditas Therapeutics US INC. | $55,384.23 | 2022-2025 | Tarpeyo |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21,236.21 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $20,438.79 | 2019-2024 | Lokelma |
| Ardelyx, INC. | $296.98 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Mallinckrodt Hospital Products INC. | $136.64 | 2025 | Terlivaz |
| Amgen INC. | $122.10 | 2025 | |
| Alexion Pharmaceuticals, INC. | $111.34 | 2021 | |
| Baxter Healthcare | $109.22 | 2019 | |
| Akebia Therapeutics INC | $96.02 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $95.62 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.76 | 2023 | Livtencity |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $31.48 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.85 | 2025 | Jardiance |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Kamgar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.